{"id":"NCT00915525","sponsor":"Allergan","briefTitle":"Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-02-01","primaryCompletion":"2014-08-05","completion":"2014-08-05","firstPosted":"2009-06-08","resultsPosted":"2015-12-18","lastUpdate":"2019-04-30"},"enrollment":829,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Overactive Bladder","Urinary Incontinence"],"interventions":[{"type":"BIOLOGICAL","name":"botulinum toxin Type A","otherNames":["BOTOXÂ®"]}],"arms":[{"label":"botulinum toxin Type A 100U","type":"EXPERIMENTAL"},{"label":"botulinum toxin Type A 150U","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the long term safety and effectiveness of botulinum toxin type A in treating patients with idiopathic overactive bladder with urinary incontinence.","primaryOutcome":{"measure":"Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes","timeFrame":"Study Baseline, Week 12 Treatment Cycle 1","effectByArm":[{"arm":"Botulinum Toxin Type A 100U","deltaMin":5.55,"sd":3.617}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":8,"countries":["United States","Belgium","Canada","Czechia","Germany","Poland","Russia","United Kingdom"]},"refs":{"pmids":["27038769"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":71,"n":829},"commonTop":["Urinary Tract Infection","Bacteriuria","Dysuria","Back Pain","Urinary Retention"]}}